Early Tuesday, Donald Trump signed an executive order in the Oval Office aimed at expediting the review process for psychedelic drugs, including ibogaine. This marks a pivotal moment in the ongoing conversation about mental health treatments.
Ibogaine is derived from a plant native to West Africa. It has been used to treat conditions such as post-traumatic stress disorder (PTSD), anxiety, and addiction in some countries.
The executive order directs the Department of Health and Human Services to allocate at least $50 million for states developing programs focused on psychedelic drugs. Advocacy groups have long pushed for more research into psychedelics for treating various mental health issues.
As of midday, it remains unclear how the federal government will facilitate further research into ibogaine. The FDA is reportedly taking steps to enable the first human trials of ibogaine within the United States.
Ibogaine continues to be classified as a Schedule I drug in the U.S., which complicates its availability and research potential. Nevertheless, a small study indicated that ibogaine could safely reduce PTSD symptoms in veterans when combined with intravenous magnesium.
At least 27 people have died after taking ibogaine, according to a 2023 report. This raises concerns about its safety despite its potential benefits. Trump acknowledged these risks during the signing event, jokingly asking, “Can I have some, please?”
The Trump administration’s initiative could open doors for federal funding aimed at further investigating ibogaine’s effectiveness. The implications of this executive order are significant for those involved in mental health advocacy.
Trump stated, “If these turn out to be as good as people are saying, it’s going to have a tremendous impact.” His comments reflect a growing interest in alternative therapies amid rising mental health crises across the nation.